Discontinued operations → Net profit: $21.7BRevenue → Gross profit: $14.7BPharmaceutical → Revenue: $13.9BMedical devices → Revenue: $7.5BRevenue → Cost of revenue: $6.6BGross profit → SG&A: $5.4BGross profit → Operating profit: $5.0BImmunology → Pharmaceutical: $4.8BOncology → Pharmaceutical: $4.5BOperating profit → Net profit: $4.3BGross profit → R&D: $3.4BSurgery → Medical devices: $2.5BOrthopaedics → Medical devices: $2.2BNeuroscience → Pharmaceutical: $1.7BInterventional → Medical devices: $1.6BVision → Medical devices: $1.3BOther pharma → Pharmaceutical: $1.0BPulmonary → Pharmaceutical: $1.0BOperating profit → Tax: $0.9BInfectious diseases → Pharmaceutical: $0.9BGross profit → Other expense: $0.5BGross profit → In-process R&D: $0.2BInterest → Operating profit: $0.2BGross profit → Restructuring: $0.2BImmunology: $4.8BPharmaceutical: $13.9BInfectious diseases: $0.9BNeuroscience: $1.7BOncology: $4.5BPulmonary: $1.0BOther pharma: $1.0BRevenue: $21.4BMedical devices: $7.5BInterventional: $1.6BOrthopaedics: $2.2BSurgery: $2.5BVision: $1.3BGross profit: $14.7BCost of revenue: $6.6BOperating profit: $5.2BSG&A: $5.4BR&D: $3.4BIn-process R&D: $0.2BRestructuring: $0.2BOther expense: $0.5BNet profit: $26.0BInterest: $0.2BDiscontinued operations: $21.7BTax: $0.9Bcreated with SankeyArt.comImmunology$4.8B13% Y/YPharmaceutical$13.9B5% Y/YInfectious diseases$0.9BNeuroscience$1.7BOncology$4.5BPulmonary$1.0BOther pharma$1.0BRevenue$21.4B7% Y/YMedical devices$7.5B10% Y/YInterventional$1.6BOrthopaedics$2.2BSurgery$2.5BVision$1.3BGross profit$14.7B7% Y/YCost of revenue$6.6B7% Y/YOperating profit$5.2B1% Y/YSG&A$5.4B9% Y/YR&D$3.4B-1% Y/YIn-process R&D$0.2BRestructuring$0.2BOther expense$0.5BNet profit$26.0B484% Y/YInterest$182M84% Y/YDiscontinued operations$21.7B14575% Y/YTax$0.9B5% Y/YJohnson & Johnson Q3 FY23 Income Statement
2022
Q4 Full Year
2023
Q1 Q2 Q3 Q4 Full Year
2024
Q1 Q2